AAAAAA

   
Results: 1-13 |
Results: 13
7-alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines - potent inhibitors of the tyrosine kinase c-Src
Authors: Widler, L Green, J Missbach, M Susa, M Altmann, E
Citation: L. Widler et al., 7-alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines - potent inhibitors of the tyrosine kinase c-Src, BIOORG MED, 11(6), 2001, pp. 849-852
7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d] pyrimidines - Potent inhibitors of the tyrosine kinase c-Src
Authors: Altmann, E Missbach, M Green, J Susa, M Wagenknecht, HA Widler, L
Citation: E. Altmann et al., 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d] pyrimidines - Potent inhibitors of the tyrosine kinase c-Src, BIOORG MED, 11(6), 2001, pp. 853-856
Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: Can we define subgroups of patients benefiting most from primary angioplasty? Results from the pooled data of the Maximal Individual Therapyin Acute Myocardial Infarction Registry and the Myocardial Infarction Registry
Authors: Zahn, R Schiele, R Schneider, S Gitt, AK Wienbergen, H Seidl, K Voigtlander, T Gottwik, M Berg, G Altmann, E Rosahl, W Senges, J
Citation: R. Zahn et al., Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: Can we define subgroups of patients benefiting most from primary angioplasty? Results from the pooled data of the Maximal Individual Therapyin Acute Myocardial Infarction Registry and the Myocardial Infarction Registry, J AM COL C, 37(7), 2001, pp. 1827-1835
Necrotizing colitis as primary manifestation of Buerger's disease
Authors: Munch, D Altmann, E
Citation: D. Munch et E. Altmann, Necrotizing colitis as primary manifestation of Buerger's disease, VASA, 30(4), 2001, pp. 289-292
Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology - Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA 1+2) Registries and the Myocardial Infarction Registry (MIR)
Authors: Gottwik, M Zahn, R Schiele, R Schneider, S Gitt, AK Fraunberger, L Bossaller, C Glunz, HG Altmann, E Rosahl, W Senges, J
Citation: M. Gottwik et al., Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology - Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA 1+2) Registries and the Myocardial Infarction Registry (MIR), EUR HEART J, 22(19), 2001, pp. 1794-1801
Effect of preinfarction angina pectoris on outcome in patients with acute myocardial infarction treated with primary angioplasty (results from the Myocardial Infarction Registry [MIR])
Authors: Zahn, R Schiele, R Schneider, S Gitt, AK Seidl, K Bossaller, C Schuler, G Gottwik, M Altmann, E Rosahl, W Senges, J
Citation: R. Zahn et al., Effect of preinfarction angina pectoris on outcome in patients with acute myocardial infarction treated with primary angioplasty (results from the Myocardial Infarction Registry [MIR]), AM J CARD, 87(1), 2001, pp. 1-6
Impact of prehospital delay on mortality in patients with acute myocardialinfarction treated with primary angioplasty and intravenous thrombolysis
Authors: Zahn, R Schiele, R Gitt, AK Schneider, S Seidl, K Voigtlander, T Gottwik, M Altmann, E Gieseler, U Rosahl, W Wagner, S Senges, J
Citation: R. Zahn et al., Impact of prehospital delay on mortality in patients with acute myocardialinfarction treated with primary angioplasty and intravenous thrombolysis, AM HEART J, 142(1), 2001, pp. 105-111
Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: Potent inhibitors of the tyrosine kinase c-Src
Authors: Missbach, M Altmann, E Widler, L Susa, M Buchdunger, E Mett, H Meyer, T Green, J
Citation: M. Missbach et al., Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: Potent inhibitors of the tyrosine kinase c-Src, BIOORG MED, 10(9), 2000, pp. 945-949
Decreasing hospital mortality between 1994 and 1998 in patients with acutemyocardial infarction treated with primary angioplasty but not in patientstreated with intravenous thrombolysis - Results from the pooled data of the Maximal Individual Therapy in acute myocardial infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR)
Authors: Zahn, R Schiele, R Schneider, S Gitt, AK Wienbergen, H Seidl, K Bossaller, C Buttner, HJ Gottwik, M Altmann, E Rosahl, W Senges, J
Citation: R. Zahn et al., Decreasing hospital mortality between 1994 and 1998 in patients with acutemyocardial infarction treated with primary angioplasty but not in patientstreated with intravenous thrombolysis - Results from the pooled data of the Maximal Individual Therapy in acute myocardial infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR), J AM COL C, 36(7), 2000, pp. 2064-2071
Transfer of patients with acute myocardial infarction for primary or acuteangioplasty from hospitals without the facilities to perform angioplasty -Results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the myocardial infarction registry(MIR)
Authors: Zahn, R Schiele, R Schneider, S Gitt, AK Heer, T Wienbergen, H Gottwik, M Altmann, E Grube, R Becker, G Baumgartel, B Senges, J
Citation: R. Zahn et al., Transfer of patients with acute myocardial infarction for primary or acuteangioplasty from hospitals without the facilities to perform angioplasty -Results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the myocardial infarction registry(MIR), HERZ, 25(7), 2000, pp. 667-675
Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction - A phase II dose escalation, randomized, double-blind study
Authors: Ronner, E van Kesteren, HAM Zijnen, P Altmann, E Molhoek, PG van der Wieken, LR Cuffie-Jackson, CA Neuhaus, KL Simoons, ML
Citation: E. Ronner et al., Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction - A phase II dose escalation, randomized, double-blind study, EUR HEART J, 21(18), 2000, pp. 1530-1536
Multicenter evaluation on the efficacy and tolerability of repeated Prostavasin (R) treatment in patients with stage III IV PAOD
Authors: Scheffler, P Altmann, E Camci, M Creutzig, A Diehm, C Gruss, J Heidrich, H Horsch, S Lill, G Nullen, H Rogatti, W Rudofsky, G Waldhausen, P Weiss, T
Citation: P. Scheffler et al., Multicenter evaluation on the efficacy and tolerability of repeated Prostavasin (R) treatment in patients with stage III IV PAOD, VASA, 1999, pp. 30-36
Acute myocardial infarction in Germany between 1996 and 1998: Therapy and intrahospital course. Results of the myocardial infarction registry (MIR) in Germany
Authors: Wagner, S Schneider, S Schiele, R Fischer, F Dehn, H Grube, R Becker, G Baumgartel, B Altmann, E Senges, J
Citation: S. Wagner et al., Acute myocardial infarction in Germany between 1996 and 1998: Therapy and intrahospital course. Results of the myocardial infarction registry (MIR) in Germany, Z KARDIOL, 88(10), 1999, pp. 857-867
Risultati: 1-13 |